Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Eli Lilly Says Phase III Study Of Cialis Meets Primary Endpoint - Quick Facts

Eli Lilly & Co (LLY: Quote) Tuesday announced that a Phase III study showed both Cialis and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia, or BPH.

The randomized, double-blind, placebo-controlled, parallel-group, 12-week trial, conducted in 44 urology centers in 10 countries, assessed the efficacy and safety of Cialis 5 mg for daily use in parallel with tamsulosin 0.4 mg in men aged 45 years and older with signs and symptoms of BPH.

The company stated that Cialis improved erectile dysfunction in those men who had both signs and symptoms of BPH and ED.

The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin.

Click here to receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Nike Inc., the world's largest athletic shoes and apparel maker, said Thursday after the markets closed that its second quarter profit rose 23% from last year, helped by higher revenue and improved gross margin. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. Citing extreme fluctuation of the ruble, Apple Inc. (AAPL) has reportedly discontinued its online sales of products in Russia. Despite efforts of the Russian central bank, the ruble has been spiraling downward, with oil prices plunging to historic levels. The ruble shed around 19 percent on Wednesday.... General Motors said it has halted the delivery of cars to dealerships in Russia as it strives to overcome the business risks stemming from the collapse of the ruble.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.